1. Cell Cycle/DNA Damage Epigenetics Cytoskeleton Immunology/Inflammation
  2. HDAC Collagen Interleukin Related Microtubule/Tubulin
  3. GV-001

GV-001 是一种具有选择性的口服活性 HDAC6 抑制剂,对 HDAC6IC50 为 1.18 nM。GV-001 可选择性增强 α-tubulin 的乙酰化水平,降低 sIL-6 和 I 型胶原蛋白 (Collagen I) 水平,抑制肾囊肿生长,并上调 PC1 的表达。GV-001 可用于常染色体显性多囊肾病 (ADPKD) 的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

GV-001

GV-001 Chemical Structure

CAS No. : 3082707-76-1

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD)[1].

IC50 & Target[1]

HDAC6

1.18 nM (IC50)

IL-6

 

Collagen I

 

α-Tubulin

 

体外研究
(In Vitro)

GV-001 (6a) (2 h) 可强效且选择性地抑制重组人 HDAC6,其 IC50 为 1.18 nM,对 HDAC1 的选择性是 1991 倍,对 HDAC8 的选择性是 247 倍[1]
GV-001 (0.00152-30 μM; 16 h) 可在 HepG2 细胞中选择性上调乙酰化 α-微管蛋白,其 IC50 为 0.19 μM,相对于乙酰化组蛋白 H3 (IC50 = 4.46 μM) 显示出 24 倍的选择性[1]
GV-001 (370 nM-10 μM; 48 h) 可在无细胞毒性的浓度下调控基于人原代细胞的 MyoF 和 REMyoF 纤维化模型中关键的炎症、纤维化及组织重塑生物标志物[1]
GV-001 (0.1-100 μM; 14 days) 在三维体外人 ADPKD 模型中可强效抑制囊肿形成,其囊肿活力的 IC50 值为 0.42 μM,囊肿数量的 IC50 值为 2.22 μM,囊肿总面积的 IC50 值为 0.92 μM,平均囊肿大小的 IC50 值为 2.38 μM,且在有效浓度下无细胞毒性[1]
GV-001 (0.001-100 μM; 12 days) 可在 3D 体外人源 ADPKD 模型中强效抑制已形成囊肿的生长,其针对囊肿活力的 IC50 值为 8.36 μM,针对囊肿数量的 IC50 值为 13.3 μM,针对囊肿总面积的 IC50 值为 10.8 μM,针对平均囊肿大小的 IC50 值为 18.5 μM[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 0.00152, 0.00457, 0.0137, 0.0412, 0.123, 0.37, 1.11, 3.33, 10, 30 μM
Incubation Time: 16 h
Result: Induced dose-dependent upregulation of acetylated α-tubulin with an IC50 of 0.19 μM.
Upregulated acetylated histone H3 with an IC50 of 4.46 μM.
Resulted in a 24-fold selectivity for α-tubulin acetylation over histone H3 acetylation.
药代动力学
(Parmacokinetics)
Species Dose Route C0 T1/2 AUC0-t AUC0-∞ Cmax Tmax Bioavailability T1/2 (Plasma) AUC0-∞ (Plasma)
Rat[1] 1 mg/kg i.v. 559 ng/mL 0.173 h 98.5 ng·h/mL 99.8 ng·h/mL / / / / /
Rat[1] 30 mg/kg p.o. / 2.94 h 1018 ng·h/mL 1087 ng·h/mL 480 ng/mL 0.250 h 36 % / /
Rat[1] 30 mg/kg p.o. / / / / / / / 3.90 h 997 ng·h/mL
Mice[1] 1 mg/kg i.v. 1222 ng/mL 0.200 h 184 ng·h/mL 184 ng·h/mL / / / / /
Mice[1] 30 mg/kg p.o. / 2.49 h 643 ng·h/mL 694 ng·h/mL 635 ng/mL 0.250 h 13 % / /
Mice[1] 60 mg/kg p.o. / 5.70 h 1408 ng·h/mL 2561 ng·h/mL 834 ng/mL 0.250 h 13 % / /
体内研究
(In Vivo)

GV-001 (6a) (60-120 mg/kg;口服;每日一次;连续 14 天) 可显著降低转基因 ADPKD 小鼠模型中的囊肿进展 (囊肿指数分别降至 22.7% 和 20.7%),并上调 PC1 的表达[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 Tg(Ubi-emGFP Pkd1miRNA)1SJi/Narl transgenic mice (males and females, 14 days old at study start, stable Pkd1 knockdown via miRNA expression)[1]
Dosage: 60 mg/kg; 120 mg/kg
Administration: p.o.; daily; 14 days
Result: Reduced the average kidney-to-body weight ratio to 3.4% and reduced the cystic index to 22.7%.
Reduced the average kidney-to-body weight ratio to 3.2% and reduced the cystic index to 20.7%.
Increased PC1 positive area.
分子量

309.32

Formula

C17H15N3O3

CAS 号
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
GV-001
目录号:
HY-182904
需求量: